|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...90919293949596979899100...39323933» |
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma (clinicaltrials.gov) - Jul 19, 2024
P1, N=6, Terminated, Sponsor: Inge Marie Svane
N=12 --> 6 | Recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Jun 2024; Lack of supply of scaffolds for T-cell expansion Evaluation of step A did not support addition of pembrolizumab in step B
- | dalnicastobart (LVGN7409) / Lyvgen, pradusinstobart (LVGN3616) / Lyvgen
Enrollment open: CD40 Agonist and PD-1 Inhibitor in HNSCC (clinicaltrials.gov) - Jul 19, 2024
P1, N=20, Recruiting, Sponsor: University of Pennsylvania
N=12 --> 6 | Recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Jun 2024; Lack of supply of scaffolds for T-cell expansion Evaluation of step A did not support addition of pembrolizumab in step B Not yet recruiting --> Recruiting
- |||| ianalumab (VAY736) / Novartis
Trial primary completion date: NEPTUNUS-2: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (clinicaltrials.gov) - Jul 19, 2024
P3, N=489, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2026 --> May 2025
- INCB99280 / Incyte
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3637;
- mRNA-4157 / Merck (MSD), Moderna, Keytruda (pembrolizumab) / Merck (MSD)
INTerpath-005: phase 2 study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3634;
- Balversa (erdafitinib) / J&J, cetrelimab (JNJ-63723283) / J&J
SOGUG-NEOWIN: A Phase 2, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations. (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3633;
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase 3 VOLGA trial (Bilbao Auditorium - Hall 2) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3583;
- Keytruda (pembrolizumab) / Merck (MSD)
Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3564;
- ifinatamab deruxtecan (DS-7300) / Daiichi Sankyo, Merck (MSD), Tecentriq (atezolizumab) / Roche
IDeate-Lung03: A Phase 1b/2 study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3461;
- PT217 / Phanes Therap
SKYBRIDGE Study: An Open-label, Multicenter, Dose Escalation and Dose Expansion Phase 1/2 Study of PT217 as a Monotherapy and in Combination with an ICI and/or Chemotherapy, in Patients with SCLC, LCNEC and EP-NEC Known to Express DLL3 (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3460;
- Zynyz (retifanlimab-dlwr) / Incyte, Pemazyre (pemigatinib) / Incyte
PERELI, a phase 2, open label, multicenter study of PEmigatinib and REtifanlimab in advanced dedifferentiated LIposarcoma (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3435;
- Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis
Novel serum glycoproteomic biomarkers predict response to Nivolumab plus Cabozantinib (NIVO+CABO) versus Sunitinib (SUN) in advanced RCC (aRCC): analysis from CheckMate 9ER (Bilbao Auditorium - Hall 2) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3355;
- JNJ-9401 / J&J, JNJ-8343 / J&J
A Phase 1, First-in-Human, Open-Label, Multicenter, Trial-in-Progress of the Safety, Tolerability, and Preliminary Efficacy of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined with JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3322;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, pimicotinib (ABSK021) / Abbisko, Conmana (icotinib) / Betta Pharma
A multicenter, open-label phase II study to evaluate the efficacy and safety of Pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without Toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) . (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3210;
- Keytruda (pembrolizumab) / Merck (MSD), PT886 / Phanes Therap
TWINPEAK Phase 1/2 Study, PT886 a Bispecific Antibody Targeting Claudin 18.2 and CD47 in Combination with Chemotherapy and/or Pembrolizumab in Gastric/GEJ-Carcinomas or PDAC (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3208;
- Tyvyt (sintilimab) / Eli Lilly, Fruzaqla (fruquintinib) / Takeda
Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase 1b/2 clinical trial (FUNCTION) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3155;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Aidixi (disitamab vedotin) / Pfizer
A randomized phase 2 study of Disitamab Vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3154;
- Kaitanni (cadonilimab) / Akesobio
Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients. (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3153;
- Imfinzi (durvalumab) / AstraZeneca
Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3152;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Tagrisso (osimertinib) / AstraZeneca
Osimertinib Combined with Dalpiciclib in EGFR-Mutant, CDK4/6 Pathway-Altered, Advanced NSCLC Patients with Acquired Resistance to Third-Generation EGFR-TKIs: A Phase 2, Prospective, Multicenter, Single-Arm Clinical Trial (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3079;
- Krazati (adagrasib) / BMS, Keytruda (pembrolizumab) / Merck (MSD)
KRYSTAL-7: a phase 3 study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3077;
- livmoniplimab (ABBV-151) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD), budigalimab (ABBV-181) / AbbVie
A Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab (Livmo) in Combination With Budigalimab (Budi) Plus Chemotherapy (CT) vs Pembrolizumab (Pembro) Plus CT in Untreated Metastatic Non-Small Cell Lung Cancer (mNSCLC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3076;
- Keytruda (pembrolizumab) / Merck (MSD), MK-1084 / Merck (MSD), Otsuka
Phase 3 Study of Pembrolizumab Plus MK-1084 vs Pembrolizumab Plus Placebo as First-Line Treatment for Metastatic Non (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3075;
- Keytruda (pembrolizumab) / Merck (MSD)
TACTC-2 trial:Efficacy of Pembrolizumab (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3074;
- Keytruda (pembrolizumab) / Merck (MSD)
Impact of concomitant co-medications on survival with first-line pembrolizumab in 43,000 French patients with advanced NSCLC (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3003;
Trial primary completion date: Mar 2026 --> May 2025 This study, using a comprehensive French database encompassing all patients with incident lung cancer treated with pembrolizumab between 2015 and 2022, supports the safety of co-medications with STD and ATB, and suggests that PPI exposure is associated with worse OS.
- Tevimbra (tislelizumab-jsgr) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
NEO-PIONEER:Neoadjuvant Hypofractionated Radiotherapy plus Tislelizumab with Anlotinib Followed by Adjuvant Tislelizumab with Anlotinib in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC): A Phase II Trial in Progress (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2935;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159 (Barcelona Auditorium - Hall 2) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2905;
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2850;
- xirestomig (ATG-101) / Antengene
A phase I trial of ATG-101, an investigational PD-L1 (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2792;
- Keytruda (pembrolizumab) / Merck (MSD), BI-1910 / BioInvent
A Phase 1/2a First in-Human Phase 1 Study of BI 1910, a Monoclonal Antibody Agonistic to TNFR2, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2790;
- PF-08046049 / Pfizer
Phase 1 study of the investigational CD228 x 4-1BB costimulatory antibody Anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2788;
- Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD), Yervoy (ipilimumab) / BMS
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): expanded analyses from CheckMate 9DW (Bilbao Auditorium - Hall 2) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2697;
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Five-year overall survival (OS) and OS by tumour response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC) (Bilbao Auditorium - Hall 2) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2679;
- Jemperli (dostarlimab-gxly) / GSK
JADE: A phase (ph) 3 study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2677;
- petosemtamab (MCLA-158) / Merus, Keytruda (pembrolizumab) / Merck (MSD)
Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1 (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2676;
- VB10.16 / Nykode Therap, Keytruda (pembrolizumab) / Merck (MSD)
A Phase 1/2a, Open-label, Dose-finding Trial to Evaluate Safety, Immunogenicity, and Anti-tumour Activity of VB10.16 in Combination with Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2673;
- mRNA-4157 / Merck (MSD), Moderna, Keytruda (pembrolizumab) / Merck (MSD)
INTerpath-007: A phase 2/3, adaptive, randomized study of neoadjuvant and adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) for treatment of resectable locally advanced (LA) cutaneous squamous cell carcinoma (cSCC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2672;
- Trodelvy (sacituzumab govitecan-hziy) / Gilead, Keytruda (pembrolizumab) / Merck (MSD)
Phase II TROPHY-IO-HN study of pembrolizumab (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2670;
- Yinuokai (orelabrutinib) / InnoCare, Biogen, Rituxan (rituximab) / Roche
Fixed-duration orelabrutinib plus bendamustine and rituximab versus continuous Bruton Tyrosine Kinase inhibitor (BTKi) in treatment-na (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2586;
- Yinuokai (orelabrutinib) / InnoCare, Biogen, Rituxan (rituximab) / Roche
Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2584;
- Tevimbra (tislelizumab-jsgr) / BeiGene
Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study. (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2555;
- Yutuo (zimberelimab) / Arcus Biosci, Gilead, Aidixi (disitamab vedotin) / Pfizer
Disitamab Vedotin and Zimberelimab combined with Stereotactic Body Radiation Therapy for the Treatment of Recurrent, Metastatic Cervical Cancer: A Single-Arm, Open-Label, Phase II Study (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2552;
- Yidafan (ivonescimab) / Akesobio, Summit Therapeutics, ligufalimab (AK117) / Akesobio
The efficacy and safety of ivonescimab with or without ligufalimab in combination with FOLFOXIRI as first-line (1L) treatment for metastatic colorectal cancer (mCRC) (Granada Auditorium - Hall 6) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2403;
- Tecentriq (atezolizumab) / Roche
Molecular imaging of Programmed Death Ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) in patients with metastatic Triple Negative Breast Cancer (mTNBC): the MIMIR-study. (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2350;
- sacituzumab tirumotecan (MK-2870) / Merck (MSD), Keytruda (pembrolizumab) / Merck (MSD)
Phase 3, Randomized, Open-label TroFuse-010 Study of Sacituzumab Tirumotecan (sac-TMT) Alone and With Pembrolizumab vs Treatment of Physician's Choice Chemotherapy (TPC) in Patients With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (mBC) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2348;
- Tecentriq (atezolizumab) / Roche
NeoBREASTIM (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2246;
- Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Aidixi (disitamab vedotin) / Pfizer
A Randomized, Multicenter, Open-Label Phase II Neoadjuvant Study to Evaluate the Safety and Efficacy of HER2-ADC Disitamab Vedotin in Combination Toripalimab or Sequence Chemotherapy in Participants With HR-negative, HER2 Low-expressing Breast Cancer (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2244;
- tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
A Phase II, Open Label, Randomized, Non-Comparative Cohorts study of adjuvant Atezolizumab or Atezolizumab plus Tiragolumab in Solid Tumors with resectable disease with Intermediate-High Risk of recurrence and high Tumor Mutational Burden (TMB-H) Or Microsatellite Instability (MSI-H) (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_2165;
- | bintrafusp alfa (M7824) / EMD Serono, PDS01ADC / PDS Biotech, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Trial primary completion date, Metastases: A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (clinicaltrials.gov) - Jul 18, 2024
P1/2, N=107, Recruiting, Sponsor: National Cancer Institute (NCI)
This study, using a comprehensive French database encompassing all patients with incident lung cancer treated with pembrolizumab between 2015 and 2022, supports the safety of co-medications with STD and ATB, and suggests that PPI exposure is associated with worse OS. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
- |||||| Promacta (eltrombopag) / Novartis
Enrollment open: CETB115G1401: Revolade Tablets Specified Drug-use Survey (clinicaltrials.gov) - Jul 18, 2024
P=N/A, N=10, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025 Not yet recruiting --> Recruiting